GenMark Q4 Revenues Fall 31 Percent, Beat Analyst Estimates | GenomeWeb

NEW YORK (GenomeWeb News) – GenMark Diagnostics reported after the close of the market on Tuesday that its revenues in the fourth quarter fell 31 percent year over year, but the company still beat the average Wall Street estimate on the top and bottom lines.

The Carlsbad, Calif.-based molecular diagnostics firm reported $6.5 million in total revenues for the three months ended Dec. 31, 2013, compared to $9.4 million in the year-ago fourth quarter and besting the consensus Wall Street estimate of $6.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.